OphtAI, a successful example of technology transfer
OphtAI is the result of a successful public-private R&D partnership between renowned industry partners, researchers, and clinical practitioners, going back more than ten years. In its most recent incarnation, it took the form of the RetinOpTIC project.
This project – a Unique Interministerial Fund (FUI 19) winner and backed by Systematic Paris-Region and Medicen clusters, set out to develop a portable digital imaging device for the retina, and a software package based on Artificial Intelligence to grade Diabetic Retinopathy. The project has a number of partners, including ADCIS, AP-HP, Evolucare and INSERM, and contributions from the very best medical and scientific experts in the field.
The creation of a joint venture between Evolucare, SME expert in care organization and patient data management, and ADCIS, SME expert in image analysis in a range of fields, makes the transfer of the OphtAI technology and its arrival onto the ophthalmology market official.
The partnership’s success illustrates the strategic positioning of clinical partners, researchers, and industry, determinedly focused on digital health and precision medicine.
OphtAI : our aim ?
The OphtAI technology sets out to revolutionize the screening of eye diseases, to help overcome a shortage of ophthalmologists. It is a disruptive innovation whose ambition is to optimize the organization of treatment in ophtalmology.
OphtAI’s promise is to support medical practice and improve the quality and availability of treatment for patients.
Our areas of expertise
The partnership between Evolucare and ADCIS, two key industry players who have been working on innovative, ambitious research projects for many years, is aiming to occupy a solid position on the international ophtalmology market with a range of innovative services based on artificial intelligence (AI).
The first solution from this range, a CE marked medical device, is used for the semi-automated screening of diabetic retinopathy (DR). By 2020, OphtAI will offer a range of more than ten services to meet the needs of practitioners and patients.
The ambition of the OphtAI joint venture is to develop an entire range of specialist ophtalmology software, covering everything from analysis of the surface of the eye with the cornea, all the way to the retina. The use of AI and deep learning in image processing and analysis paves the way for massive screening of retinal diseases, in real time and at a low cost.
Who is EVOLUCARE ?
The Group serves almost 4500 healthcare establishments, and has now launched a strategy of international expansion. Harnessing its expertise on patient data management and treatment coordination, in 2016 Evolucare moved into open innovation in e-health, to add to its initial range of decision-making services.
This strategy, embodied by Evolucare Labs, aims to develop collaborative projects in 4P medicine (personalized, preventative, predictive, participative), using artificial intelligence as the foundation. The projects developed as part of this strategy are grouped around four strategic themes :
- Support to diagnosis ;
- Support to therapeutic strategy;
- Support to remote patient monitoing;
- Support to optimization and coordination of care.
Who is ADCIS ?
Since 2008, ADCIS has been developing advanced diagnosis tools for the retina and the anterior segment of the eye by controlling acquisition systems and providing an accurate analysis of different diseases. Thanks to its subsidiary in the USA and its network of specialist retailers, thousands of users all over the world have placed their trust in ADCIS’ software to develop extremely innovative solutions.
The men behind the machine
OphtAI is home to men and women from a range of backgrounds and fields, who pool their strengths and cutting edge expertise to propose high added-value services for ophthalmology professionals.
Two leaders are found at the helm of this amazing adventure that’s all about people.
Photos : a few members of the OphtAI team. Signing the joint venture with Alexandre Le Guilcher (left) and Bruno Laÿ (right)
Alexandre LE GUILCHER, CEO, OphtAI - Director R&I, Evolucare
Following these two distinct experiences (SME and industry), in 2007 he joined Evolucare, the leading group in electronic patient record through its subsidiary, Corwin. Alexandre then began his career in the family SME, now a SME, with an extensive period in the field where he mastered the solutions on offer and gained a solid understanding of customer needs, all with the aim of improving patient treatments as a developer.
He then worked in roles as the director of roll-out and software production, then in marketing and new products, before forming the R&I division where, in 2019, OphtAI was created, a company that he manages today.
Bruno LAŸ, CTO, OphtAI - CEO ADCIS
After founding and managing NOESIS between 1985 and 1995, a company specializing in the development of scientific software, and image processing in particular, in 1995 he founded ADCIS in partnership with the American company, AAI (Amerinex Applied Imaging, Inc.).
Since 1995, he has served as VP Marketing and Sales at AAI, CEO of ADCIS and, more recently, CTO of OphtAI, of which he is co-founder with Alexandre Le Guilcher.
OphtAI enjoys major support from expert clinical practitioners, renowned in their fields. Convinced of AI’s relevance to ophthalmology and the disruptive innovation that OphtAI brings to the practical coordination of ophthalmology, partners serve as true ambassadors to the community.
Among our supporters, we can count :